FSME-IMMUN/TicoVac

On July 30, Pfizer (NYSE: PFE) announced that it had entered into a definitive agreement to acquire Baxter International's (NYSE: BAX) portfolio of marketed vaccines in a deal that is reportedly worth $635 million. The portfolio of vaccines consists of NeisVac-C and FSME-IMMUN/TicoVac....